MET stock forecast, quote, news & analysis

Key Takeaways

• MetLife shares have risen roughly 4% over the past 30 days, climbing from about $97 to trade above $100 and near a 52-week high of $102.43.
• The move has been supported by a wave of analyst price-target increases and rating upgrades from firms including Barclays, UBS, Piper Sandler, JPMorgan, and Wells Fargo.
• MetLife reported second-quarter adjusted earnings per share of $2.43, up about 20% year over year and above consensus, alongside a new $3 billion share-buyback authorization.
• The company declared a fourth-quarter 2026 dividend of $0.5925 per share and is scheduled to report third-quarter results on November 4, 2026.
• Consensus analyst sentiment remains a "Buy," with an average price target in the range of roughly $105 to $107.

Current Market Snapshot

MetLife, Inc. (MET) has been trading with notable momentum, recently reclaiming the $100 level and approaching its 52-week high of $102.43. The stock's move from around $97 to roughly $101 over the trailing 30 days reflects a gain of approximately 4%, a steady advance rather than a sharp, single-catalyst spike. The shares sit well above their 52-week low of $67.33 and carry a market capitalization of roughly $63 billion.

Broader sentiment across the life-insurance sector has been constructive, with investors weighing steady demand for group benefits, favorable mortality trends, and the industry's sensitivity to interest rates and capital-return programs. For MetLife, the recent climb has been reinforced by a series of positive analyst actions and a sustained track record of earnings beats, helping the stock hold near record territory.

MetLife (MET) Business Overview and Competitive Position

Founded in 1868, MetLife is one of the world's leading financial services companies, providing insurance, annuities, employee benefits, and asset management to individual and institutional customers. The company operates in more than 40 markets and holds leading positions in the United States, Asia, Latin America, Europe, and the Middle East. Its core businesses span group life, dental, and disability coverage, retirement and income solutions, and the MetLife Investment Management asset-management franchise.

MetLife's competitive strengths include a diversified geographic footprint, a well-known brand, scale across group benefits, and a disciplined capital framework that prioritizes earnings growth, expense efficiency, and shareholder returns. Investors follow the stock closely for its earnings quality, its "New Frontier" efficiency program, and its ability to generate free cash flow that supports dividends and buybacks.

Recent Developments Driving MET

The past 30 days brought a steady flow of analyst activity. Barclays raised its price target to $111 from $97 while maintaining an Overweight rating, UBS lifted its target to $110 from $105, and TD Cowen moved to $110 from $105. Piper Sandler upgraded the stock to Overweight from Neutral, and JPMorgan and Wells Fargo both raised targets to $110. Mizuho trimmed its target to $109 from $112 but kept an Outperform rating, while Raymond James maintained a Hold.

These revisions followed a strong second quarter, when MetLife posted adjusted earnings per share of $2.43, up roughly 20% year over year and ahead of the $2.30 consensus, and authorized a $3 billion share-repurchase program. In October, the board declared a fourth-quarter 2026 dividend of $0.5925 per share, payable December 8 to holders of record on November 3. Separately, Fitch affirmed MetLife's ratings with a stable outlook, and MetLife Investment Management closed its Galaxy 38 collateralized loan obligation. The company also pointed to AI-oriented initiatives, including integrating its pet-insurance portal through a ChatGPT plugin.

Trending AI Robots

For traders seeking a data-driven edge, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of automated bots that trade thousands of tickers, but only the top-performing and most relevant strategies are featured in this section. The bots vary in approach, timeframe, and performance metrics, allowing users to compare momentum, swing, and longer-horizon strategies across different markets. Browsing the section can help investors understand how algorithmic systems are positioning in names like MetLife and identify patterns that may complement their own research.

2026 Outlook and What Investors Should Watch

Looking ahead, the most immediate catalyst is MetLife's third-quarter earnings release on November 4, 2026, with the conference call scheduled for November 5. Consensus estimates point to earnings of about $2.69 per share, up from $2.37 in the prior-year period. Investors will focus on adjusted earnings growth, expense-ratio trends under the New Frontier program, and the trajectory of variable investment income.

Beyond earnings, key themes include the direction of long-term interest rates, which influence MetLife's investment income and reserve assumptions, as well as demand across group benefits and retirement and income solutions. Capital-return execution, including progress on the $3 billion buyback and future dividend decisions, remains a focal point. Competitive pressures in the life-insurance industry and macroeconomic conditions across international markets will also shape the stock's path through the remainder of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations